Weston Kightlinger
Chief Executive Officer Ridge Biotechnologies, Inc.
Seminars
Thursday 30th July 2026
AI Design of NativeLink Bioconjugation Enzymes to Increase Effectiveness and Lower Systemic Toxicity
9:00 am
- Leveraging experiment-informed AI design of enzymes that provide site-specific conjugation to native antibodies that create homogeneous ADCs and AOCs of uniform DAR and increased stability.
- Understanding stability improvements over traditional maleimides that cause premature payload release, yielding ADCs with greater efficacy and lower systemic toxicity than approved ADCs, applicable to both single- and dual-payload formats.
- Building massive enzyme specificity datasets and AI-guided design strategies to design tunable linkers cleavage motifs for tumor-selective payload release.
